Trusted Resources: Education
Scientific literature and patient education texts
Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated With Nusinersen
source: Journal of neuromuscular diseases
authors: Kelly A. Rich, Ashley Fox, Mehmet Yalvac, Sarah Heintzman, Marco Tellez, Amy Bartlett, Steven Severyn, Mathew Linsenmayer, Kristina Kelly, Jerry Reynolds, Gary Brent Sterling, Tristan Weaver, Kiran Rajneesh, Megan G. Pino, W. David Arnold, Bakri Elsheikh, Stephen J. Kolbsummary/abstract:
Objective: To retrospectively evaluate the utility of serum and cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) as biomarkers for spinal muscular atrophy (SMA) progression and response to nusinersen treatment.
Methods: NfL and pNfH levels were quantified using single molecular array (SIMOA) in CSF of 33 adult SMA patients (SMN copy number 3-5) before and in response to nusinersen treatment. In 11 of the patients, blood serum samples were also collected. CSF NfL and pNfH from patients were compared to CSF Nfs from age-matched controls without neurological disease (n = 6). For patients, pearson correlation coefficients (r) were calculated to investigate associations between Nf levels and other functional outcome measures.
Results: Nf levels were similar between SMA and control adults and showed no change in response to nusinersen treatment in CSF or serum. Cross-sectional analyses showed an increase in CSF NfL and pNfH with age in patients (NfL p = 0.0013; pNfH p = 0.0035) and an increase in CSF NfL in controls (p = 0.002). In non-ambulatory patients, baseline serum pNfH showed a negative correlation with multiple strength and functional assessment metrics including Revised Upper Limb Module (r = -0.822, p = 0.04), upper extremity strength (r = -0.828, p = 0.042), lower extremity strength (r = -0.860, p = 0.028), and total strength (r = -0.870, p = 0.024).
Conclusions: Nf levels did not change in response to nusinersen in adults with SMA and were not different from controls. In patients and controls, we detected an age-related increase in baseline CSF NfL and pNfH levels. Though some associations were identified, our results suggest Nf levels are not preditive or prognostic biomarkers in this population.
organization: The Ohio State University Wexner Medical Center, USA
Every Day You Don’t Lose, You Are WinningJennifer Summers, 35, is an optimistic, ...
Adult-Onset Non-5q Proximal Spinal Muscular Atrophy: A Comprehensive ReviewBackground: Adult-onset spinal muscular ...
Spine Surgery Effective in SMA Type 1 Children, But Not Without RisksSurgery to correct kyphoscoliosis — a ...
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA ConferenceBiogen Inc. announced new data and updat...
FDA-Approved Treatment Provides Life-Saving Miracle for Girl With Spinal Muscular AtrophyAlex says her daughter made it to Norton...
Coverage of Genetic Therapies for Spinal Muscular Atrophy Across Fee-for-Service Medicaid ProgramsBackground: Genetic therapies are a prom...
Axonal Excitability Changes in Children With Spinal Muscular Atrophy Treated With NusinersenSpinal muscular atrophy (SMA) is associa...